<DOC>
	<DOCNO>NCT01441388</DOCNO>
	<brief_summary>Despite success anti-angiogenic therapy multiple treatment setting , fraction patient refractory vascular endothelial growth factor ( VEGF ) inhibitor treatment majority patient eventually develop evasive resistance exhibit disease progression therapy . It propose mesenchymal-epithelial transition factor ( c-MET ) ligand hepatocyte growth factor ( HGF scatter factor ) contribute significantly VEGF inhibitor resistance combine c-MET inhibitor VEGF inhibitor provide additional clinical activity compare VEGF inhibitor alone . This hypothesis test use cMET/ALK inhibitor , crizotinib , combination individual VEGF inhibitor . Three combination prioritize , namely crizotinib plus axitinib , crizotinib plus sunitinib crizotinib plus bevacizumab , fourth combination , crizotinib plus sorafenib test crizotinib combine either axitinib and/or sunitinib .</brief_summary>
	<brief_title>A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Dose Escalation Population : Histological cytological diagnosis advanced/metastatic solid tumor resistant standard therapy standard therapy available . Lesions may measurable non measurable . Expansion Population 1 : Patients histologically confirm metastatic renal cell cancer prior systemic therapy direct malignant tumor . Expansion Population 2 : Patients histologically confirm metastatic renal cell cancer whose prior systemic therapy direct malignant tumor single agent VEGF inhibitor acquire resistance treatment . Resistance define progression follow initial response ( complete partial ) , stable disease least 6 month single agent VEGF inhibitor . Expansion Population 3 : Patients histologically confirm glioblastoma whose disease fail previous therapy , must include treatment external beam radiation temozolomide chemotherapy , radiographically recurrent progressive disease . Expansion Population 4 : Patients histologically confirm advancedstage ( unresectable metastatic ) hepatocellular carcinoma receive previous systemic therapy direct malignant tumor eligible receive crizotinib plus sorafenib , combination test . Eligibility criterion also include normal hepatic function ChildPugh hepatic function class A . Patients hemorrhagic brain metastasis know symptomatic brain metastasis require steroid . Major surgery within 4 week start study treatment . Radiation therapy within 2 week start study treatment . Hypertension control medication ( &gt; 150/90 mmHg despite optimal medical therapy ) . For glioblastoma patient : Prior treatment glioblastoma Gliadel wafer , stereotactic radiation , brachytherapy unless pathological definitive radiological evidence ( PET scan perfusion MRI ) recurrent tumor unless new enhancement outside radiation field . History Grade 2 great acute intracranial hemorrhage . Radiation therapy ( RT ) glioblastoma within 3 month unless either : ) histopathologic confirmation recurrent tumor , b ) new enhancement MRI outside RT treatment field.Concomitant treatment therapeutic dos anticoagulant ( low dose warfarin ( Coumadin ) 2 mg PO daily deep vein thrombosis prophylaxis allow ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Phase 1b</keyword>
	<keyword>crizotinib</keyword>
	<keyword>sunitinib</keyword>
	<keyword>axitinib</keyword>
	<keyword>sorafenib</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>cMET inhibitor</keyword>
	<keyword>VEGF inhibitor</keyword>
	<keyword>crizotinib combination</keyword>
</DOC>